Psoralen plus ultraviolet A irradiation (PUVA) has immunomodulatory effects and is used to treat a variety of immune-mediated @entity66 . We administered PUVA to 103 @entity1 for treatment of @entity479 -resistant @entity2132 ( @entity2132 ) of the skin. Twenty-nine @entity1 had related donors (12 HLA-mismatched) and 74 had unrelated donors (23 HLA-mismatched). The median onset of @entity2132 was day 13 after transplantation, and the median onset of PUVA treatment was day 46. PUVA was administered as secondary therapy for 86 @entity1 and tertiary therapy or greater for 17 @entity1 . The median number of treatments was 16, and the mean cumulative exposure was 41 J/cm2. PUVA was generally well tolerated with 8 @entity1 discontinuing therapy because of @entity137 . At the start of PUVA treatment, 48 @entity1 had @entity1910 affecting >50% of their body surface area (BSA), and 91 had @entity1910 involving >25% BSA. Of 65 @entity1 who were evaluated after 6 weeks of PUVA treatment, 11 still had @entity1910 involving >50% BSA, 24 had @entity1910 involving >25% BSA, and 24 had no @entity1910 . The mean daily dose of @entity229 at the start of PUVA therapy was 1.6 mg/kg compared to 0.7 mg/kg after 6 weeks of therapy. Fifty-nine @entity1 (57%) did not require additional therapy for skin @entity2132 after starting PUVA. Ninety-two percent of @entity1 developed chronic @entity2132 . Fifty-three @entity1 (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for @entity479 -resistant acute @entity2132 of the skin.

Psoralen and ultraviolet A irradiation (PUVA) as therapy for XXXX -resistant cutaneous @entity2132 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['dermatologic diseases'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'acute graft-versus-host disease'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity479 :: (D013256,Chemical) :: ['steroid']
